Literature DB >> 22495708

Morbidity of selective lymph node biopsy for melanoma: meta-analysis of complications.

Emanuele Cigna1, Angela Gradilone, Diego Ribuffo, Paola Gazzaniga, Pasquale Fino, Valentina Sorvillo, Nicolò Scuderi.   

Abstract

BACKGROUND AND AIM: Intraoperative lymphatic mapping and selective lymph node biopsy is accepted worldwide as the standard procedure for staging regional lymph nodes of 1-4 mm thick melanomas, as well as for other neoplasms. Although it is often stated that selective lymph node biopsy is a minimally invasive procedure associated with few complications, few data exist concerning the morbidity associated with the procedure. The present analysis was performed to evaluate the morbidity associated with selective lymph node biopsy in a long-term follow-up.
MATERIALS AND METHODS: The study provides a review of 437 selective lymph node biopsies on 269 patients, operated on between the 1994 and the 2009, for the lymph node biopsy of head and neck, groin, axilla, upper and lower limbs and nodal basins. Patients' history and follow-up were reviewed for 2 weeks after surgery, every 3 months for the first 2 years, every 4 months during the third year, and every 6 months subsequently, and postoperative morbidity was evaluated.
RESULTS: After sentinel node biopsy, 14 patients developed one of the following complications: hematoma, 1 case (0.30%); lymphedema, 1 case (0.30%); seroma, 2 cases (0.61%); wound infection, 6 cases (1.83%); keloid scar, 2 cases (0.61%); and postoperative pain, 2 cases (0.61%). The total complication rate was 4.26%.
CONCLUSIONS: Selective lymph node biopsy for melanoma, as for other tumors, in respect to radical lymphadenectomy, is not a complications-free procedure but is usually not severe.

Entities:  

Mesh:

Year:  2012        PMID: 22495708     DOI: 10.1177/030089161209800113

Source DB:  PubMed          Journal:  Tumori        ISSN: 0300-8916


  5 in total

1.  Sentinel lymph node biopsy in early melanoma-comparison of two techniques for sentinel removal.

Authors:  Uwe Wollina; Dana Langner; Jacqueline Schönlebe; Carmen Tanner; Martin Fuchs; Andreas Nowak
Journal:  Wien Med Wochenschr       Date:  2016-08-30

2.  In vivo and in silico pharmacokinetics and biodistribution of a melanocortin receptor 1 targeted agent in preclinical models of melanoma.

Authors:  Narges K Tafreshi; Ariosto Silva; Veronica C Estrella; Timothy W McCardle; Tingan Chen; Yolaine Jeune-Smith; Mark C Lloyd; Steven A Enkemann; Keiran S M Smalley; Vernon K Sondak; Josef Vagner; David L Morse
Journal:  Mol Pharm       Date:  2013-07-08       Impact factor: 4.939

3.  Synthesis and characterization of a melanoma-targeted fluorescence imaging probe by conjugation of a melanocortin 1 receptor (MC1R) specific ligand.

Authors:  Narges K Tafreshi; Xuan Huang; Valerie E Moberg; Natalie M Barkey; Vernon K Sondak; Haibin Tian; David L Morse; Josef Vagner
Journal:  Bioconjug Chem       Date:  2012-11-27       Impact factor: 4.774

4.  Lymphovenous Anastomoses and Microscopic Lymphatic Ligations for the Treatment of Persistent Lymphocele.

Authors:  Semra Uyulmaz; Andrea Planegger; Lisanne Grünherz; Pietro Giovanoli; Nicole Lindenblatt
Journal:  Plast Reconstr Surg Glob Open       Date:  2021-02-18

5.  Using the Merlin assay for reducing sentinel lymph node biopsy complications in melanoma: a retrospective cohort study.

Authors:  Tina J Hieken; Mariana B Sadurní; Enrica Quattrocchi; Ajdin Kobic; Sindhuja Sominidi-Damodaran; Jvalini T Dwarkasing; Lisette Meerstein-Kessel; Alina G Bridges; Alexander Meves
Journal:  Int J Dermatol       Date:  2022-01-31       Impact factor: 3.204

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.